ID   EPHB1_HUMAN             Reviewed;         984 AA.
AC   P54762; A8K593; B3KTB2; B5A969; O43569; O95142; O95143; Q0VG87;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   10-MAY-2017, entry version 184.
DE   RecName: Full=Ephrin type-B receptor 1;
DE            EC=2.7.10.1;
DE   AltName: Full=ELK;
DE   AltName: Full=EPH tyrosine kinase 2;
DE   AltName: Full=EPH-like kinase 6;
DE            Short=EK6;
DE            Short=hEK6;
DE   AltName: Full=Neuronally-expressed EPH-related tyrosine kinase;
DE            Short=NET;
DE   AltName: Full=Tyrosine-protein kinase receptor EPH-2;
DE   Flags: Precursor;
GN   Name=EPHB1; Synonyms=ELK, EPHT2, HEK6, NET;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Fetal brain;
RX   PubMed=8666391; DOI=10.1006/geno.1995.9985;
RA   Tang X.X., Biegel J.A., Nycum L.M., Yoshioka A., Brodeur G.M.,
RA   Pleasure D.E., Ikegaki N.;
RT   "cDNA cloning, molecular characterization, and chromosomal
RT   localization of NET(EPHT2), a human EPH-related receptor protein-
RT   tyrosine kinase gene preferentially expressed in brain.";
RL   Genomics 29:426-437(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION IN CELL ADHESION,
RP   FUNCTION IN JUN CASCADE ACTIVATION, INTERACTION WITH NCK1, MUTAGENESIS
RP   OF TYR-594 AND LYS-651, AND VARIANT TRP-973.
RC   TISSUE=Kidney;
RX   PubMed=9430661; DOI=10.1074/jbc.273.3.1303;
RA   Stein E., Huynh-Do U., Lane A.A., Cerretti D.P., Daniel T.O.;
RT   "Nck recruitment to Eph receptor, EphB1/ELK, couples ligand activation
RT   to c-Jun kinase.";
RL   J. Biol. Chem. 273:1303-1308(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), AND ALTERNATIVE SPLICING.
RX   PubMed=18593464; DOI=10.1186/ar2447;
RA   Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D.,
RA   Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.;
RT   "Novel splice variants derived from the receptor tyrosine kinase
RT   superfamily are potential therapeutics for rheumatoid arthritis.";
RL   Arthritis Res. Ther. 10:R73-R73(2008).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R.,
RA   Buhay C.J., Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R.,
RA   Gunaratne P., Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V.,
RA   Hume J., Jackson A., Khan Z.M., Kovar-Smith C., Lewis L.R.,
RA   Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D., Wei S.,
RA   Wheeler D.A., Wright M.W., Worley K.C., Yuan Y., Zhang Z., Adams C.Q.,
RA   Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clendenning J., Clerc-Blankenburg K.P., Chen R., Chen Z., Davis C.,
RA   Delgado O., Dinh H.H., Dong W., Draper H., Ernst S., Fu G.,
RA   Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., Hao B.,
RA   Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., Jackson L.R.,
RA   Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., Liu J.,
RA   Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., Palmeiri A.,
RA   Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J.,
RA   Zhang X., Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H.,
RA   Reinhardt R., Naylor S.L., Yang H., Olson M., Weinstock G.,
RA   Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 18-32.
RX   PubMed=15340161; DOI=10.1110/ps.04682504;
RA   Zhang Z., Henzel W.J.;
RT   "Signal peptide prediction based on analysis of experimentally
RT   verified cleavage sites.";
RL   Protein Sci. 13:2819-2824(2004).
RN   [8]
RP   INTERACTION WITH GRB2 AND GRB10, MUTAGENESIS OF TYR-928, AND
RP   PHOSPHORYLATION AT TYR-928.
RX   PubMed=8798570; DOI=10.1074/jbc.271.38.23588;
RA   Stein E., Cerretti D.P., Daniel T.O.;
RT   "Ligand activation of ELK receptor tyrosine kinase promotes its
RT   association with Grb10 and Grb2 in vascular endothelial cells.";
RL   J. Biol. Chem. 271:23588-23593(1996).
RN   [9]
RP   NOMENCLATURE.
RX   PubMed=9267020;
RG   Eph nomenclature committee;
RT   "Unified nomenclature for Eph family receptors and their ligands, the
RT   ephrins.";
RL   Cell 90:403-404(1997).
RN   [10]
RP   FUNCTION IN ANGIOGENESIS, FUNCTION IN CELL ADHESION, INTERACTION WITH
RP   ACP1, AND MUTAGENESIS OF TYR-928.
RX   PubMed=9499402; DOI=10.1101/gad.12.5.667;
RA   Stein E., Lane A.A., Cerretti D.P., Schoecklmann H.O., Schroff A.D.,
RA   Van Etten R.L., Daniel T.O.;
RT   "Eph receptors discriminate specific ligand oligomers to determine
RT   alternative signaling complexes, attachment, and assembly responses.";
RL   Genes Dev. 12:667-678(1998).
RN   [11]
RP   INTERACTION WITH EPHB6.
RX   PubMed=11713248; DOI=10.1074/jbc.M108011200;
RA   Freywald A., Sharfe N., Roifman C.M.;
RT   "The kinase-null EphB6 receptor undergoes transphosphorylation in a
RT   complex with EphB1.";
RL   J. Biol. Chem. 277:3823-3828(2002).
RN   [12]
RP   INTERACTION WITH GRB7, FUNCTION, PHOSPHORYLATION AT TYR-928, AND
RP   MUTAGENESIS OF TYR-928.
RX   PubMed=12223469; DOI=10.1074/jbc.M203165200;
RA   Han D.C., Shen T.L., Miao H., Wang B., Guan J.L.;
RT   "EphB1 associates with Grb7 and regulates cell migration.";
RL   J. Biol. Chem. 277:45655-45661(2002).
RN   [13]
RP   FUNCTION IN CELL MIGRATION, FUNCTION IN ERK CASCADE ACTIVATION,
RP   INTERACTION WITH GRB2; SHC1 AND SRC, AND MUTAGENESIS OF TYR-600 AND
RP   TYR-778.
RX   PubMed=12925710; DOI=10.1083/jcb.200302073;
RA   Vindis C., Cerretti D.P., Daniel T.O., Huynh-Do U.;
RT   "EphB1 recruits c-Src and p52Shc to activate MAPK/ERK and promote
RT   chemotaxis.";
RL   J. Cell Biol. 162:661-671(2003).
RN   [14]
RP   FUNCTION IN ERK CASCADE ACTIVATION, UBIQUITINATION BY CBL, INTERACTION
RP   WITH CBL, MUTAGENESIS OF LYS-651, AUTOPHOSPHORYLATION, IDENTIFICATION
RP   OF EFNB1 AS LIGAND, AND SUBCELLULAR LOCATION.
RX   PubMed=18034775; DOI=10.1111/j.1600-0854.2007.00679.x;
RA   Fasen K., Cerretti D.P., Huynh-Do U.;
RT   "Ligand binding induces Cbl-dependent EphB1 receptor degradation
RT   through the lysosomal pathway.";
RL   Traffic 9:251-266(2008).
RN   [15]
RP   STRUCTURE BY NMR OF 899-984.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the C-terminal SAM-domain of mouse ephrin type-
RT   B receptor 1 precursor (EC 2.7.1.112).";
RL   Submitted (JUL-2007) to the PDB data bank.
RN   [16]
RP   STRUCTURE BY NMR OF 434-528.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structures of the FN3 domain of human ephrin type-B receptor
RT   1.";
RL   Submitted (FEB-2009) to the PDB data bank.
RN   [17]
RP   VARIANTS [LARGE SCALE ANALYSIS] VAL-18; MET-387; THR-707; VAL-719;
RP   GLN-743; THR-912 AND MET-981.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Receptor tyrosine kinase which binds promiscuously
CC       transmembrane ephrin-B family ligands residing on adjacent cells,
CC       leading to contact-dependent bidirectional signaling into
CC       neighboring cells. The signaling pathway downstream of the
CC       receptor is referred to as forward signaling while the signaling
CC       pathway downstream of the ephrin ligand is referred to as reverse
CC       signaling. Cognate/functional ephrin ligands for this receptor
CC       include EFNB1, EFNB2 and EFNB3. During nervous system development,
CC       regulates retinal axon guidance redirecting ipsilaterally
CC       ventrotemporal retinal ganglion cells axons at the optic chiasm
CC       midline. This probably requires repulsive interaction with EFNB2.
CC       In the adult nervous system together with EFNB3, regulates
CC       chemotaxis, proliferation and polarity of the hippocampus neural
CC       progenitors. In addition to its role in axon guidance plays also
CC       an important redundant role with other ephrin-B receptors in
CC       development and maturation of dendritic spines and synapse
CC       formation. May also regulate angiogenesis. More generally, may
CC       play a role in targeted cell migration and adhesion. Upon
CC       activation by EFNB1 and probably other ephrin-B ligands activates
CC       the MAPK/ERK and the JNK signaling cascades to regulate cell
CC       migration and adhesion respectively. {ECO:0000269|PubMed:12223469,
CC       ECO:0000269|PubMed:12925710, ECO:0000269|PubMed:18034775,
CC       ECO:0000269|PubMed:9430661, ECO:0000269|PubMed:9499402}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- SUBUNIT: Heterotetramer upon binding of the ligand. The
CC       heterotetramer is composed of an ephrin dimer and a receptor
CC       dimer. Oligomerization is probably required to induce biological
CC       responses (By similarity). Interacts with EPHB6;
CC       transphosphorylates EPHB6 to form an active signaling complex.
CC       Interacts with PICK1 (By similarity). Interacts (through Tyr-594)
CC       with NCK1 (via SH2 domain); activates the JUN cascade to regulate
CC       cell adhesion (By similarity). The ligand-activated form interacts
CC       (through Tyr-928) with GRB7 and GRB10 (via SH2 domains). The
CC       ligand-activated form interacts (residues within the catalytic
CC       domain) with GRB2 (via SH2 domain). Interacts with GRB2, SHC1 and
CC       SRC; activates the MAPK/ERK cascade to regulate cell migration.
CC       Interacts with CBL; regulates receptor degradation through
CC       ubiquitination. Interacts with ACP1. {ECO:0000250,
CC       ECO:0000269|PubMed:11713248, ECO:0000269|PubMed:12223469,
CC       ECO:0000269|PubMed:12925710, ECO:0000269|PubMed:18034775,
CC       ECO:0000269|PubMed:8798570, ECO:0000269|PubMed:9430661,
CC       ECO:0000269|PubMed:9499402}.
CC   -!- INTERACTION:
CC       Q13322:GRB10; NbExp=2; IntAct=EBI-80252, EBI-80275;
CC       P62993:GRB2; NbExp=2; IntAct=EBI-80252, EBI-401755;
CC       Q14451:GRB7; NbExp=4; IntAct=EBI-80252, EBI-970191;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:18034775};
CC       Single-pass type I membrane protein {ECO:0000269|PubMed:18034775}.
CC       Early endosome membrane {ECO:0000269|PubMed:18034775}. Cell
CC       projection, dendrite {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P54762-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P54762-5; Sequence=VSP_056017;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=P54762-6; Sequence=VSP_056018, VSP_056019;
CC   -!- TISSUE SPECIFICITY: Preferentially expressed in brain.
CC   -!- PTM: Phosphorylated. Autophosphorylation is stimulated by the
CC       ligand EFNB1. Required for interaction with SH2 domain-containing
CC       interactors, for activation of the MAPK/ERK and JUN signaling
CC       cascades and for ubiquitination by CBL.
CC       {ECO:0000269|PubMed:12223469, ECO:0000269|PubMed:18034775,
CC       ECO:0000269|PubMed:8798570}.
CC   -!- PTM: Ubiquitinated; (EFNB1)ligand-induced poly- and/or multi-
CC       ubiquitination by CBL is regulated by SRC and leads to lysosomal
CC       degradation. {ECO:0000269|PubMed:18034775}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB94627.1; Type=Miscellaneous discrepancy; Note=wrong intron-exon boundaries.; Evidence={ECO:0000305};
CC       Sequence=AAB94628.1; Type=Miscellaneous discrepancy; Note=wrong intron-exon boundaries.; Evidence={ECO:0000305};
CC       Sequence=AAD02031.1; Type=Miscellaneous discrepancy; Note=Chimeric cDNA.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L40636; AAB08520.1; -; mRNA.
DR   EMBL; AF037331; AAD02030.1; -; mRNA.
DR   EMBL; AF037332; AAD02031.1; ALT_SEQ; mRNA.
DR   EMBL; AF037333; AAB94627.1; ALT_SEQ; mRNA.
DR   EMBL; AF037334; AAB94628.1; ALT_SEQ; mRNA.
DR   EMBL; EU826607; ACF47643.1; -; mRNA.
DR   EMBL; AK095305; BAG53024.1; -; mRNA.
DR   EMBL; AK291208; BAF83897.1; -; mRNA.
DR   EMBL; AC016931; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC016951; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC063918; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC073244; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC092969; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC111744; AAI11745.1; -; mRNA.
DR   CCDS; CCDS46921.1; -. [P54762-1]
DR   RefSeq; NP_004432.1; NM_004441.4. [P54762-1]
DR   UniGene; Hs.116092; -.
DR   PDB; 2DJS; NMR; -; A=434-528.
DR   PDB; 2EAO; NMR; -; A=899-984.
DR   PDB; 3ZFX; X-ray; 2.50 A; A/B/C/D/E/F/G/H/I=602-896.
DR   PDBsum; 2DJS; -.
DR   PDBsum; 2EAO; -.
DR   PDBsum; 3ZFX; -.
DR   ProteinModelPortal; P54762; -.
DR   SMR; P54762; -.
DR   BioGrid; 108361; 13.
DR   IntAct; P54762; 8.
DR   MINT; MINT-1519362; -.
DR   STRING; 9606.ENSP00000381097; -.
DR   BindingDB; P54762; -.
DR   ChEMBL; CHEMBL5072; -.
DR   GuidetoPHARMACOLOGY; 1830; -.
DR   iPTMnet; P54762; -.
DR   PhosphoSitePlus; P54762; -.
DR   BioMuta; EPHB1; -.
DR   DMDM; 1706663; -.
DR   EPD; P54762; -.
DR   MaxQB; P54762; -.
DR   PaxDb; P54762; -.
DR   PeptideAtlas; P54762; -.
DR   PRIDE; P54762; -.
DR   DNASU; 2047; -.
DR   Ensembl; ENST00000398015; ENSP00000381097; ENSG00000154928. [P54762-1]
DR   Ensembl; ENST00000493838; ENSP00000419574; ENSG00000154928. [P54762-5]
DR   GeneID; 2047; -.
DR   KEGG; hsa:2047; -.
DR   UCSC; uc003eqt.4; human. [P54762-1]
DR   CTD; 2047; -.
DR   DisGeNET; 2047; -.
DR   GeneCards; EPHB1; -.
DR   HGNC; HGNC:3392; EPHB1.
DR   HPA; HPA067740; -.
DR   MIM; 600600; gene.
DR   neXtProt; NX_P54762; -.
DR   OpenTargets; ENSG00000154928; -.
DR   PharmGKB; PA27824; -.
DR   eggNOG; KOG0196; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   GeneTree; ENSGT00760000118975; -.
DR   HOGENOM; HOG000233856; -.
DR   HOVERGEN; HBG062180; -.
DR   InParanoid; P54762; -.
DR   KO; K05110; -.
DR   OMA; KDHAEIN; -.
DR   OrthoDB; EOG091G00W0; -.
DR   PhylomeDB; P54762; -.
DR   TreeFam; TF315608; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-2682334; EPH-Ephrin signaling.
DR   Reactome; R-HSA-3928662; EPHB-mediated forward signaling.
DR   Reactome; R-HSA-3928664; Ephrin signaling.
DR   Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells.
DR   SignaLink; P54762; -.
DR   SIGNOR; P54762; -.
DR   ChiTaRS; EPHB1; human.
DR   EvolutionaryTrace; P54762; -.
DR   GeneWiki; EPH_receptor_B1; -.
DR   GenomeRNAi; 2047; -.
DR   PMAP-CutDB; P54762; -.
DR   PRO; PR:P54762; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000154928; -.
DR   CleanEx; HS_EPHB1; -.
DR   ExpressionAtlas; P54762; baseline and differential.
DR   Genevisible; P54762; HS.
DR   GO; GO:0030424; C:axon; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0030425; C:dendrite; IEA:UniProtKB-SubCell.
DR   GO; GO:0031901; C:early endosome membrane; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0032433; C:filopodium tip; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0008046; F:axon guidance receptor activity; IEA:Ensembl.
DR   GO; GO:0032403; F:protein complex binding; IEA:Ensembl.
DR   GO; GO:0005005; F:transmembrane-ephrin receptor activity; IDA:UniProtKB.
DR   GO; GO:0001525; P:angiogenesis; IDA:UniProtKB.
DR   GO; GO:0007411; P:axon guidance; ISS:UniProtKB.
DR   GO; GO:0048593; P:camera-type eye morphogenesis; IEA:Ensembl.
DR   GO; GO:0060326; P:cell chemotaxis; IDA:UniProtKB.
DR   GO; GO:0031589; P:cell-substrate adhesion; IDA:UniProtKB.
DR   GO; GO:0021952; P:central nervous system projection neuron axonogenesis; ISS:UniProtKB.
DR   GO; GO:0060996; P:dendritic spine development; ISS:UniProtKB.
DR   GO; GO:0060997; P:dendritic spine morphogenesis; ISS:UniProtKB.
DR   GO; GO:0050965; P:detection of temperature stimulus involved in sensory perception of pain; ISS:UniProtKB.
DR   GO; GO:0048013; P:ephrin receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0030010; P:establishment of cell polarity; ISS:UniProtKB.
DR   GO; GO:0001771; P:immunological synapse formation; IEA:Ensembl.
DR   GO; GO:0061351; P:neural precursor cell proliferation; ISS:UniProtKB.
DR   GO; GO:0022008; P:neurogenesis; ISS:UniProtKB.
DR   GO; GO:0021631; P:optic nerve morphogenesis; IEA:Ensembl.
DR   GO; GO:0051965; P:positive regulation of synapse assembly; ISS:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0046328; P:regulation of JNK cascade; IDA:UniProtKB.
DR   GO; GO:1901214; P:regulation of neuron death; IMP:UniProtKB.
DR   GO; GO:0031290; P:retinal ganglion cell axon guidance; ISS:UniProtKB.
DR   CDD; cd10476; EphR_LBD_B1; 1.
DR   CDD; cd00063; FN3; 2.
DR   Gene3D; 2.60.120.260; -; 1.
DR   Gene3D; 2.60.40.10; -; 2.
DR   InterPro; IPR027936; Eph_TM.
DR   InterPro; IPR034231; EphB1_rcpt_lig-bd.
DR   InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR008979; Galactose-bd-like.
DR   InterPro; IPR009030; Growth_fac_rcpt_.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001660; SAM.
DR   InterPro; IPR013761; SAM/pointed.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR011641; Tyr-kin_ephrin_A/B_rcpt-like.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016257; Tyr_kinase_ephrin_rcpt.
DR   InterPro; IPR001426; Tyr_kinase_rcpt_V_CS.
DR   Pfam; PF14575; EphA2_TM; 1.
DR   Pfam; PF01404; Ephrin_lbd; 1.
DR   Pfam; PF00041; fn3; 2.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   Pfam; PF00536; SAM_1; 1.
DR   PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00615; EPH_lbd; 1.
DR   SMART; SM01411; Ephrin_rec_like; 1.
DR   SMART; SM00060; FN3; 2.
DR   SMART; SM00454; SAM; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF47769; SSF47769; 1.
DR   SUPFAM; SSF49265; SSF49265; 1.
DR   SUPFAM; SSF49785; SSF49785; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 2.
DR   PROSITE; PS01186; EGF_2; 1.
DR   PROSITE; PS51550; EPH_LBD; 1.
DR   PROSITE; PS50853; FN3; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1.
DR   PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1.
DR   PROSITE; PS50105; SAM_DOMAIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell adhesion;
KW   Cell membrane; Cell projection; Complete proteome;
KW   Direct protein sequencing; Endosome; Glycoprotein; Kinase; Membrane;
KW   Neurogenesis; Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Receptor; Reference proteome; Repeat; Signal; Transferase;
KW   Transmembrane; Transmembrane helix; Tyrosine-protein kinase;
KW   Ubl conjugation.
FT   SIGNAL        1     17       {ECO:0000269|PubMed:15340161}.
FT   CHAIN        18    984       Ephrin type-B receptor 1.
FT                                /FTId=PRO_0000016824.
FT   TOPO_DOM     18    540       Extracellular. {ECO:0000255}.
FT   TRANSMEM    541    563       Helical. {ECO:0000255}.
FT   TOPO_DOM    564    984       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       19    201       Eph LBD. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00883}.
FT   DOMAIN      322    432       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      433    528       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      619    882       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      911    975       SAM. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00184}.
FT   NP_BIND     625    633       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOTIF       982    984       PDZ-binding. {ECO:0000255}.
FT   COMPBIAS    183    319       Cys-rich.
FT   ACT_SITE    744    744       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     651    651       ATP. {ECO:0000305}.
FT   MOD_RES     600    600       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:P54753}.
FT   MOD_RES     928    928       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   CARBOHYD    334    334       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    426    426       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    480    480       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   VAR_SEQ       1    439       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_056017.
FT   VAR_SEQ     158    242       VNTEVRSFGPLTRNGFYLAFQDYGACMSLLSVRVFFKKCPS
FT                                IVQNFAVFPETMTGAESTSLVIARGTCIPNAEEVDVPIKLY
FT                                CNG -> LALQGHSRPARKLKAAPTAPPTAAPLQRRLPSAP
FT                                VGPVITERTLTLQKWHALASHQVPAMLSPSSMRRPSFWSGT
FT                                LQGRQVGGMM (in isoform 3).
FT                                {ECO:0000303|PubMed:18593464}.
FT                                /FTId=VSP_056018.
FT   VAR_SEQ     243    984       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:18593464}.
FT                                /FTId=VSP_056019.
FT   VARIANT      18     18       M -> V (in dbSNP:rs55650774).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042165.
FT   VARIANT      87     87       T -> S (in dbSNP:rs1042794).
FT                                /FTId=VAR_011801.
FT   VARIANT     152    152       G -> R (in dbSNP:rs1042793).
FT                                /FTId=VAR_011802.
FT   VARIANT     367    367       R -> G (in dbSNP:rs1042789).
FT                                /FTId=VAR_011803.
FT   VARIANT     387    387       T -> M (in dbSNP:rs56396912).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042166.
FT   VARIANT     485    485       R -> S (in dbSNP:rs1042788).
FT                                /FTId=VAR_011804.
FT   VARIANT     707    707       S -> T (in an ovarian undifferentiated
FT                                carcinoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042167.
FT   VARIANT     719    719       I -> V (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042168.
FT   VARIANT     743    743       R -> Q (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042169.
FT   VARIANT     847    847       M -> T (in dbSNP:rs1042785).
FT                                /FTId=VAR_011805.
FT   VARIANT     912    912       A -> T (in dbSNP:rs56345346).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042170.
FT   VARIANT     973    973       R -> W (in dbSNP:rs1042784).
FT                                {ECO:0000269|PubMed:9430661}.
FT                                /FTId=VAR_058479.
FT   VARIANT     981    981       T -> M (in dbSNP:rs56186270).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042171.
FT   MUTAGEN     594    594       Y->F: Loss of interaction with NCK1.
FT                                {ECO:0000269|PubMed:9430661}.
FT   MUTAGEN     600    600       Y->F: Loss of interaction with SHC1 and
FT                                SRC. {ECO:0000269|PubMed:12925710}.
FT   MUTAGEN     651    651       K->R: Kinase-dead mutant. Unable to
FT                                autophosphorylate, to interact with SH2
FT                                domain-containing interactors, to
FT                                activate the MAPK/ERK and JUN signaling
FT                                cascades. Not ubiquitinated by CBL.
FT                                {ECO:0000269|PubMed:18034775,
FT                                ECO:0000269|PubMed:9430661}.
FT   MUTAGEN     778    778       Y->F: Loss of interaction with SHC1.
FT                                {ECO:0000269|PubMed:12925710}.
FT   MUTAGEN     928    928       Y->F: Disrupts binding with the GRB10 SH2
FT                                domain, providing evidence for
FT                                phosphorylation. Disrupts interaction
FT                                with GRB7 and ACP1.
FT                                {ECO:0000269|PubMed:12223469,
FT                                ECO:0000269|PubMed:8798570,
FT                                ECO:0000269|PubMed:9499402}.
FT   CONFLICT     12     12       A -> E (in Ref. 2; AAD02030/AAB94627/
FT                                AAB94628). {ECO:0000305}.
FT   CONFLICT    185    185       S -> I (in Ref. 2; AAD02030/AAD02031/
FT                                AAB94627/AAB94628). {ECO:0000305}.
FT   CONFLICT    274    274       T -> R (in Ref. 2; AAD02030/AAD02031/
FT                                AAB94627/AAB94628). {ECO:0000305}.
FT   CONFLICT    336    336       T -> S (in Ref. 2; AAD02030/AAD02031/
FT                                AAB94627/AAB94628). {ECO:0000305}.
FT   CONFLICT    752    752       V -> L (in Ref. 6; AAI11745).
FT                                {ECO:0000305}.
FT   CONFLICT    813    813       V -> H (in Ref. 2; AAD02030/AAB94627).
FT                                {ECO:0000305}.
FT   CONFLICT    819    819       S -> Y (in Ref. 2; AAD02030/AAB94627).
FT                                {ECO:0000305}.
FT   CONFLICT    881    881       M -> I (in Ref. 4; BAF83897).
FT                                {ECO:0000305}.
FT   CONFLICT    903    903       L -> H (in Ref. 4; BAF83897).
FT                                {ECO:0000305}.
FT   STRAND      441    445       {ECO:0000244|PDB:2DJS}.
FT   STRAND      447    453       {ECO:0000244|PDB:2DJS}.
FT   STRAND      464    473       {ECO:0000244|PDB:2DJS}.
FT   STRAND      482    495       {ECO:0000244|PDB:2DJS}.
FT   STRAND      501    512       {ECO:0000244|PDB:2DJS}.
FT   STRAND      514    517       {ECO:0000244|PDB:2DJS}.
FT   STRAND      521    524       {ECO:0000244|PDB:2DJS}.
FT   HELIX       616    618       {ECO:0000244|PDB:3ZFX}.
FT   STRAND      619    626       {ECO:0000244|PDB:3ZFX}.
FT   STRAND      633    638       {ECO:0000244|PDB:3ZFX}.
FT   STRAND      646    652       {ECO:0000244|PDB:3ZFX}.
FT   HELIX       659    672       {ECO:0000244|PDB:3ZFX}.
FT   STRAND      683    687       {ECO:0000244|PDB:3ZFX}.
FT   STRAND      689    692       {ECO:0000244|PDB:3ZFX}.
FT   STRAND      694    698       {ECO:0000244|PDB:3ZFX}.
FT   HELIX       705    710       {ECO:0000244|PDB:3ZFX}.
FT   TURN        711    714       {ECO:0000244|PDB:3ZFX}.
FT   HELIX       718    737       {ECO:0000244|PDB:3ZFX}.
FT   HELIX       747    749       {ECO:0000244|PDB:3ZFX}.
FT   STRAND      750    752       {ECO:0000244|PDB:3ZFX}.
FT   STRAND      758    760       {ECO:0000244|PDB:3ZFX}.
FT   HELIX       793    798       {ECO:0000244|PDB:3ZFX}.
FT   HELIX       803    818       {ECO:0000244|PDB:3ZFX}.
FT   TURN        824    827       {ECO:0000244|PDB:3ZFX}.
FT   HELIX       830    838       {ECO:0000244|PDB:3ZFX}.
FT   HELIX       851    860       {ECO:0000244|PDB:3ZFX}.
FT   HELIX       865    867       {ECO:0000244|PDB:3ZFX}.
FT   HELIX       871    883       {ECO:0000244|PDB:3ZFX}.
FT   HELIX       885    888       {ECO:0000244|PDB:3ZFX}.
FT   STRAND      889    891       {ECO:0000244|PDB:3ZFX}.
FT   HELIX       916    921       {ECO:0000244|PDB:2EAO}.
FT   TURN        922    924       {ECO:0000244|PDB:2EAO}.
FT   HELIX       926    928       {ECO:0000244|PDB:2EAO}.
FT   HELIX       929    935       {ECO:0000244|PDB:2EAO}.
FT   HELIX       940    943       {ECO:0000244|PDB:2EAO}.
FT   HELIX       948    954       {ECO:0000244|PDB:2EAO}.
FT   HELIX       959    975       {ECO:0000244|PDB:2EAO}.
SQ   SEQUENCE   984 AA;  109885 MW;  8044160E24E93A92 CRC64;
     MALDYLLLLL LASAVAAMEE TLMDTRTATA ELGWTANPAS GWEEVSGYDE NLNTIRTYQV
     CNVFEPNQNN WLLTTFINRR GAHRIYTEMR FTVRDCSSLP NVPGSCKETF NLYYYETDSV
     IATKKSAFWS EAPYLKVDTI AADESFSQVD FGGRLMKVNT EVRSFGPLTR NGFYLAFQDY
     GACMSLLSVR VFFKKCPSIV QNFAVFPETM TGAESTSLVI ARGTCIPNAE EVDVPIKLYC
     NGDGEWMVPI GRCTCKPGYE PENSVACKAC PAGTFKASQE AEGCSHCPSN SRSPAEASPI
     CTCRTGYYRA DFDPPEVACT SVPSGPRNVI SIVNETSIIL EWHPPRETGG RDDVTYNIIC
     KKCRADRRSC SRCDDNVEFV PRQLGLTECR VSISSLWAHT PYTFDIQAIN GVSSKSPFPP
     QHVSVNITTN QAAPSTVPIM HQVSATMRSI TLSWPQPEQP NGIILDYEIR YYEKEHNEFN
     SSMARSQTNT ARIDGLRPGM VYVVQVRART VAGYGKFSGK MCFQTLTDDD YKSELREQLP
     LIAGSAAAGV VFVVSLVAIS IVCSRKRAYS KEAVYSDKLQ HYSTGRGSPG MKIYIDPFTY
     EDPNEAVREF AKEIDVSFVK IEEVIGAGEF GEVYKGRLKL PGKREIYVAI KTLKAGYSEK
     QRRDFLSEAS IMGQFDHPNI IRLEGVVTKS RPVMIITEFM ENGALDSFLR QNDGQFTVIQ
     LVGMLRGIAA GMKYLAEMNY VHRDLAARNI LVNSNLVCKV SDFGLSRYLQ DDTSDPTYTS
     SLGGKIPVRW TAPEAIAYRK FTSASDVWSY GIVMWEVMSF GERPYWDMSN QDVINAIEQD
     YRLPPPMDCP AALHQLMLDC WQKDRNSRPR FAEIVNTLDK MIRNPASLKT VATITAVPSQ
     PLLDRSIPDF TAFTTVDDWL SAIKMVQYRD SFLTAGFTSL QLVTQMTSED LLRIGITLAG
     HQKKILNSIH SMRVQISQSP TAMA
//
